Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com
by Amy Steele · The Cerbat GemStockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Five stocks we like better than Genocea Biosciences
- Why Invest in 5G? How to Invest in 5G Stocks
- How Much Can You Make in Stocks in One Month?
- Where to Find Earnings Call Transcripts
- This Is the Top Large-Cap Stock Insiders Are Buying
- Consumer Discretionary Stocks Explained
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside